TTD | Drug: D00EQY

Drug General Information
Drug ID	D00EQY
Former ID	DIB008094
Drug Name	KTN3379
Drug Type	Antibody
Indication	Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10:C00-C75, C7A, C7B, D10-D36, D3A]		Phase 1	[524573]
Company	Kolltan pharmaceuticals
Target and Pathway
Target(s)	Receptor protein-tyrosine kinase erbB-3	Target Info		[544480]
KEGG Pathway	ErbB signaling pathway
	Calcium signaling pathway
	Endocytosis
	Proteoglycans in cancer
	MicroRNAs in cancer
NetPath Pathway	TNFalpha Signaling Pathway
PANTHER Pathway	Cadherin signaling pathway
PANTHER Pathway	EGF receptor signaling pathway
Pathway Interaction Database	ErbB2/ErbB3 signaling events
	ErbB receptor signaling network
	a6b1 and a6b4 Integrin signaling
WikiPathways	ErbB Signaling Pathway
	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Signaling Pathways in Glioblastoma
	miR-targeted genes in muscle cell - TarBase
	Heart Development
References
Ref 524573	ClinicalTrials.gov (NCT02014909) A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors. U.S. National Institutes of Health.
Ref 544480	A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4): 733-750.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information